Paul Evans Email & Phone Number

Montreal, Quebec, Ca

Recruited to lead global business development and portfolio for the generic and specialty brand divisions of Pharmascience Inc. Founded in 1983, Pharmascience is a full-service, privately-owned pharmaceutical company and is a leading manufacturer and marketer of prescription generic, over-the-counter, and behind-the-counter products as well as USFDA approved Canadian-made injectables. With strong roots in Canada and a growing global reach, the company distributes in more than 60 countries and commercializes nearly 300 product families in 20 different dosage forms for over 2,000 products. In Canada alone, more than 45 million prescriptions a year are filled with Pharmascience products.MISSION |• Cultivate a growth-oriented culture to take Pharmascience to the next level.• Catalyze a diverse team to take entrepreneurial risks and accountability.• Collaborate cross-functionally to create alignment and drive results.IMPACT |• Successfully on-boarded, executed, built strong enterprise-wide relationships, and led transition to a growth-orientation in a 100%, fully remote environment.• Created value in 6 months by catalyzing team to deliver an additional 14 in-licensing agreements generating $60m in projected 5-yr margin and reducing operating expenses by $250k.• Collaborated cross-functionally to upgrade product selection process for global alignment and investment discipline.DEFINING COMPETENCIES |Senior-level Executive Leadership | Strategic Thinking | Complex Negotiations & Partnering | Global Business Development | M&A | Portfolio Management | Legal & IP Strategy

After the successful sale of Qualitest to Endo Pharmaceuticals, I formed a strategy and business development consultancy and advisory practice. I provide leadership with expertise relative to acquisition due-diligence, target search, commercial forecasting, partnering strategy, and contract execution. With a focus on the generic & specialty pharmaceutical and CDMO space, clients include private equity, established pharmaceutical companies and start-ups looking to move their businesses to the Next Level.IMPACT |• Advised private equity on fit & valuation for 4 potential acquisitions in the $100m - $1b range• Negotiated 3 new product supply relationships valued at $10-30m revenue with a focus on IP valuation• Drove client’s search process for acquisition targets DEFINING COMPETENCIES |Complex Negotiations & Partnering | Global Business Development | M&A | Legal & IP Strategy

Round Rock, Texas, Us

London, Greater London, Gb

Recruited to lead a new venture within Johnson Matthey’s established fine chemical business. Traditionally, JM focused on supplying generic pharmaceutical companies with controlled-substance active pharmaceutical ingredients or contract development & manufacturing of APIs for innovator companies. This was an opportunity to doing something entrepreneurial – reinvigorating the pipeline of new generic APIs and changing the strategy to include drug product – to take the fine chemical business to the next level. Created a new team from scratch to focus on drug product profit-sharing partnerships; this success led to an integration with the broader business, with me stepping up to lead the global generic API business. IMPACT |• Created vision / strategic plan and obtained funding for new business unit by reviving new product pipeline and changing “go to market” strategy, including API sales and FDF profit-share partnerships.• Generated >$60m profit in 18 months by launching a profit-share partnership on new API / FDF.• Drove P&L with $250m revenue by establishing product management / strategies and cost to serve discipline. DEFINING COMPETENCIES |Senior-level Executive Leadership | Vision development | Strategic Thinking | Complex Negotiations & Partnering | Global Business Development | Portfolio Management | Legal & IP Strategy

Tel-Aviv, Il

Largest generic pharmaceutical company in the world. When I was asked to join, I thought it was a great opportunity to move my consulting practice into a full-time role across a broader range of dosage forms and markets. I worked with a great business development and alliance management team to fill holes in our US launch pipeline, mitigate launch risk and look for new products / companies that enhanced our capabilities around the world.IMPACT |• Executed partnering / in-licensing / M&A opportunities from ideation to close.• Championed and negotiated a complex manufacturing & distribution agreement for first-to-generic-market, cytotoxic chemotherapy with market value of $650m.• Negotiated and led technology license agreement for a peptide in a long-acting depot suspension with global market value of $1.6b.DEFINING COMPETENCIES |Strategic Thinking | Complex Negotiations & Partnering | Business Development

Huntsville, Al, Us

I joined this privately-held generic pharmaceutical company soon after Apax Partners acquired the business from the founders. This was a ‘roll-up your sleeves’ role as the only business development team member in a small, but experienced and hard-charging, 8-member executive team. We worked to quickly scale EBITDA and were in constant deal-making mode – either licensing products, acquiring products, acquiring companies, or positioning ourselves for an exit.IMPACT |• Increased private company’s EBITDA by $23m by leading new product selection process, developing corporate strategy, and evaluating partnering / in-licensing M&A opportunities.• Advised and executed private equity exit, completing sale to Endo Pharmaceuticals.• Realized commercial product sales potential of $4m by closing 2 licensing agreements.DEFINING COMPETENCIES |Senior-level Executive Leadership | Strategic Thinking | Complex Negotiations & Partnering | Global Business Development | M&A | Portfolio Management | Legal & IP Strategy

CEO recruited me as employee #2 at this specialty pharmaceutical start-up that was backed by Warburg-Pincus. Our focus was to build a branded portfolio of urology and female healthcare products - licensing assets with human proof of concept and then commercializing them by shepherding them through clinical development and scale-up. As a small start-up, our 5-member executive team was very hands-on and worked across functions to support each other in a collaborative way. IMPACT |• Built pipeline of phase 2 / 3 clinical NDA assets within 2 years, executing 3 licensing agreements with commercial product revenue potential of $900m.• Negotiated agreements for clinical trials, pharmacovigilance, product development, and supply.• Positioned commercialization strategy of clinical pipeline for Urologists and OB-GYNs.DEFINING COMPETENCIES |Senior-level Executive Leadership | Strategic Thinking | Complex Negotiations & Partnering | Global Business Development | Portfolio Management | Legal & IP Strategy

Us

STADA was an opportunity to pivot away from the active pharmaceutical ingredients segment - a chance to get involved in drug product business development. It was here that I discovered my affinity for leveraging partnerships to develop new generic drug products and align contract manufacturing arrangements. After heading up business development, I was asked to lead the subsidiary as its President until I helped STADA group exit the US market.IMPACT |• Drove $35m revenue base by directing new product launches and establishing accountability.• Spearheaded strategic reorganization, designing a self-sufficient, profitable business entity.• Prepared complete corporate due-diligence and pitch package for accomplishing sale of company.DEFINING COMPETENCIES |Senior-level Executive Leadership | Strategic Thinking | Complex Negotiations & Partnering | Global Business Development | Portfolio Management

Bs, Chemical Engineering

Ms, Engineering Management